NewAmsterdam Pharma (NAMS) EBIT (2023 - 2026)
NewAmsterdam Pharma's (NAMS) quarterly EBIT came in at -$58.4 million in Q1 2026, up 15.24% year-on-year from -$50.7 million in Q1 2025, and up 11.46% quarter-over-quarter from -$66.0 million in Q4 2025.
NewAmsterdam Pharma (NAMS) EBIT (2023 - 2026) Analysis & Trends
NewAmsterdam Pharma has disclosed EBIT across 4 years of filings, most recently posting -$58.4 million for Q1 2026.
- EBIT for Q1 2026 came in at -$58.4 million, up 15.24% year-over-year; the trailing twelve-month figure through Mar 2026 was -$215.2 million (down 13.41% YoY), and the FY2025 annual result was -$225.7 million, down 28.02% from the prior year.
- EBIT came in at -$58.4 million for Q1 2026 at NewAmsterdam Pharma, up from -$66.0 million in the prior quarter.
- In the past five years, EBIT ranged from a high of -$25.0 million in Q3 2024 to a low of -$68.9 million in Q1 2025.
- The 4-year median for EBIT is -$51.1 million (2023), against an average of -$49.5 million.
- Across the five-year window, EBIT jumped 49.55% in 2024 and sank 120.55% in 2025, its largest moves.
- NewAmsterdam Pharma's EBIT stood at -$51.1 million in 2023, then rose by 15.36% to -$43.2 million in 2024, then sank by 52.63% to -$66.0 million in 2025, then gained by 11.46% to -$58.4 million in 2026.
- The last three EBIT figures came in at -$58.4 million (Q1 2026), -$66.0 million (Q4 2025), and -$55.1 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | -32.68 Mn |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | -2.97 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | -19.70 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | -3.82 Mn |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | -15.76 Mn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | -1.51 Mn |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 1.14 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -65.83 Mn |
| 10 | NewAmsterdam Pharma | 3.63 Bn | 3.63 Bn | - | -58.42 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -58.42 Mn |
| Dec 31, 2025 | -65.98 Mn |
| Sep 30, 2025 | -55.14 Mn |
| Jun 30, 2025 | -35.64 Mn |
| Mar 31, 2025 | -68.93 Mn |
| Dec 31, 2024 | -43.23 Mn |
| Sep 30, 2024 | -25.00 Mn |
| Jun 30, 2024 | -52.58 Mn |
| Mar 31, 2024 | -55.48 Mn |
| Dec 31, 2023 | -51.07 Mn |
| Sep 30, 2023 | -49.56 Mn |
| Jun 30, 2023 | -42.48 Mn |
| Mar 31, 2023 | -39.85 Mn |